Retrophin Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St inches lower as tech drags, US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Retrophin (RTRX) Misses Q3 EPS by 23c, Revenues Miss
November 1, 2018 4:55 PM EDTRetrophin (NASDAQ: RTRX) reported Q3 EPS of ($0.68), $0.23 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $40.71 million versus the consensus estimate of $44.36 million.
I am pleased with the continued advancement of our first-in-class fosmetpantotenate and sparsentan programs and look... More
